Technical Analysis for ESPR - Esperion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Fell Below 20 DMA | Bearish | -0.49% | |
| Bollinger Band Squeeze | Range Contraction | -0.49% | |
| 20 DMA Support | Bullish | -4.69% | |
| Bollinger Band Squeeze | Range Contraction | -4.69% | |
| BB Squeeze Started | Range Contraction | -4.69% | |
| MACD Bearish Signal Line Cross | Bearish | -2.40% | |
| 200 DMA Resistance | Bearish | -4.69% | |
| Shooting Star Candlestick | Bearish | -4.69% |
| Alert | Time |
|---|---|
| Possible NR7 | about 17 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| Down 1% | about 21 hours ago |
| 20 DMA Resistance | about 21 hours ago |
| 10 DMA Resistance | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Low Density Lipoprotein Atherosclerosis Gabaa Receptor Positive Allosteric Modulators Niacin
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Obesity Lipid Cardiology Cholesterol Lipoprotein Low Density Lipoprotein Atherosclerosis Gabaa Receptor Positive Allosteric Modulators Niacin
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.4 |
| 52 Week Low | 0.8651 |
| Average Volume | 3,011,043 |
| 200-Day Moving Average | 2.21 |
| 50-Day Moving Average | 1.87 |
| 20-Day Moving Average | 2.06 |
| 10-Day Moving Average | 2.08 |
| Average True Range | 0.12 |
| RSI (14) | 51.69 |
| ADX | 34.15 |
| +DI | 27.04 |
| -DI | 13.59 |
| Chandelier Exit (Long, 3 ATRs) | 1.90 |
| Chandelier Exit (Short, 3 ATRs) | 2.14 |
| Upper Bollinger Bands | 2.19 |
| Lower Bollinger Band | 1.93 |
| Percent B (%b) | 0.38 |
| BandWidth | 12.64 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.07 |
| MACD Histogram | -0.0114 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.15 | ||||
| Resistance 3 (R3) | 2.16 | 2.12 | 2.13 | ||
| Resistance 2 (R2) | 2.12 | 2.09 | 2.12 | 2.12 | |
| Resistance 1 (R1) | 2.08 | 2.07 | 2.06 | 2.07 | 2.12 |
| Pivot Point | 2.04 | 2.04 | 2.04 | 2.04 | 2.04 |
| Support 1 (S1) | 2.00 | 2.01 | 1.98 | 1.99 | 1.94 |
| Support 2 (S2) | 1.96 | 1.99 | 1.96 | 1.94 | |
| Support 3 (S3) | 1.92 | 1.96 | 1.93 | ||
| Support 4 (S4) | 1.91 |
